April 2025 in “Journal of Reproductive Healthcare and Medicine” This study confirmed that an injectable implant known as RISUG-PH™, when administered via the vas deferens, successfully delivers the drug Finasteride to the prostate in male rats for up to 28 days, suggesting a potential localized alternative to oral delivery methods.
6 citations
,
March 2021 in “International Journal of Pharmaceutics” This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.
December 2022 in “International Journal of Pharmaceutics” This study estimated the starting dose range for a finasteride long-acting injectable formulation in humans, suggesting that 16.80 mg may be the optimal starting dose.
February 2026 in “MDPI (MDPI AG)” This review provides a comprehensive look at injectable treatments like PRP, stem cells, and exosomes for hair regrowth, highlighting their potential to minimize systemic and localized side effects associated with conventional medications, and improve patient care by stimulating natural hair growth.
January 2026 in “Dermatologic Surgery” In this systematic review, researchers found that injectable therapies, including agents like dutasteride and multivitamin formulations, may offer cosmetic benefits for androgenetic alopecia; however, evidence is limited by small study sizes, varied methods, and short follow-up periods, necessitating standardized trials for routine use recommendations.